Wednesday, May 13, 2026 at 11 am-12 pm ET                           Pricing: Free for Members and $99 for Non-Members

Program Description

GLP-1 agonists to treat obesity continue to challenge health plan sponsors as a major contributor to prescription drug spending, leading to widespread variation in coverage among health plans and employer groups. GLP-1 treatments for obesity hold the potential for improved health outcomes which could offset increasing prescription drug spending through reductions in medical costs. However, real-world evidence on this connection remains limited, with seemingly contradictory findings across analyses. Variation in study design and assessment contributes to these differences, creating challenges for managed care professionals seeking to leverage this evidence when making coverage decisions. This presentation will address the existing knowledge gap by reviewing the real-world evidence on GLP-1 products for obesity, exploring how variation in the design of these studies affects results, and describing how managed care decision-makers can leverage current evidence to inform GLP-1 coverage decisions.